Abbott Laboratories (ABT) on Wednesday began a recall of approximately 359 million blood-sugar test strips for diabetics. The strips, which are Abbott's Precision Xtra, Precision Xceed Pro, MediSense Optium, Optium, OptiumEZ and ReliOn Ultima blood-glucose monitoring systems, turned out to yield falsely low blood-sugar measurements

The danger is that users may not realize when their blood-sugar levels are too high or may mistakenly boost their blood sugar when it's not necessary.

Both the FDA and the company are reviewing the manufacturing process for the strips. Abbott sold the recalled strips in the U.S. and Puerto Rico between January and September of this year, according to the U.S. Food and Drug Administration (FDA).

Abbott's diabetes treatment products account for about 4% of the company's sales. Shares of the company had dipped 0.3% to $47.84 by about 7 p.m. Wednesday.

Increase your money and finance knowledge from home

Understanding Stock Market Indexes

What does it mean when people say "the market is up 2%"?

View Course »

Reading a Stock Quote

Learn to read the ingredients of a stock.

View Course »

Add a Comment

*0 / 3000 Character Maximum